Hazard ratios and 95% confidence intervals for risk of breast cancer in relation to number of nevi, stratified by menopausal status, E3N cohort (<i>n = </i>89,802).

a<p>Adjusted for age (timescale), education, age at menopause (in postmenopausal women), use of MHT (in postmenopausal women), and use of premenopausal progestogens, and stratified according to year of birth in 5-y categories (Model 2).</p>b<p>Additionally adjusted for personal history of BBD and family history of breast cancer (model used for homogeneity test) (Model 4).</p

Hazard ratios and 95% confidence intervals for risk of breast cancer in relation to number of nevi, stratified by hormonal receptor status, E3N cohort (<i>n = </i>88,387).

<p>Women with missing information on hormone receptor status were excluded from this analysis (<i>n = </i>1,415).</p>b<p>Adjusted for age (timescale), education, menopausal status, age at menopause (in postmenopausal women), use of MHT (in postmenopausal women), and use of premenopausal progestogens, and stratified according to year of birth in 5-y categories (Model 2).</p>c<p>Additionally adjusted for personal history of BBD and family history of breast cancer (model used for homogeneity test) (Model 4).</p

Hazard ratios and 95% confidence intervals for risk of breast cancer in relation to number of nevi, stratified by hormonal receptor status, E3N cohort (<i>n = </i>88,387).

<p>Women with missing information on hormone receptor status were excluded from this analysis (<i>n = </i>1,415).</p>b<p>Adjusted for age (timescale), education, menopausal status, age at menopause (in postmenopausal women), use of MHT (in postmenopausal women), and use of premenopausal progestogens, and stratified according to year of birth in 5-y categories (Model 2).</p>c<p>Additionally adjusted for personal history of BBD and family history of breast cancer (model used for homogeneity test) (Model 4).</p

Hazard ratios and 95% confidence intervals for risk of breast cancer in relation to number of nevi, E3N cohort (<i>n = </i>89,802).

a<p>Adjusted for age (timescale), education, menopausal status, age at menopause (in postmenopausal women), use of MHT (in postmenopausal women), and use of premenopausal progestogens, and stratified according to year of birth in 5-y categories.</p>b<p>Model 2 additionally adjusted for personal history of BBD.</p>c<p>Model 3 additionally adjusted for personal history of BBD and family history of breast cancer.</p>d<p>Model 4 additionally adjusted for BMI, height, physical activity, age at menarche, age at first full-term pregnancy, parity, breastfeeding, use of OCs, history of mammographic exam, UV dose in county of birth, and UV dose in county of residence at inclusion.</p

Hazard ratios and 95% confidence intervals for risk of breast cancer in relation to number of nevi, stratified by histological type of breast cancer, E3N cohort (<i>n</i> = 89,429).

a<p>Adjusted for age (timescale), education, menopausal status, age at menopause (in postmenopausal women), use of MHT (in postmenopausal women), and use of premenopausal progestogens, and stratified according to year of birth in 5-y categories (Model 2).</p>b<p>Additionally adjusted for personal history of BBD and family history of breast cancer (model used for homogeneity test) (Model 4).</p

Odds ratios and 95% confidence intervals for number of nevi in relation to family history of breast cancer, E3N cohort.

a<p>Adjusted for education and age at inclusion.</p

Odds ratios and 95% confidence intervals for number of nevi in relation to history of benign breast disease, E3N cohort.

a<p>Adjusted for age at cohort inclusion, age at last returned questionnaire, education, menopausal status, age at menopause (in postmenopausal women), use of MHT (in postmenopausal women), use of premenopausal progestogens, and family history of breast cancer.</p

Analysis of SMAD6 cg01339004 probe methylation.

<p>Ai: Boxplot of β-value methylation of cg01339004 probe as measured with Illumina 450 k beadchip in Stage 2. Aii: Boxplot of methylation level of cg01339004 probe as measured with bisulphite pyrosequencing in Stage 3. B: Volcano plot: Difference in median methylation between the two menarcheal age groups (>11 (n = 268) vs. ≤11 years, (n = 62), against the –log(P-Value) of a linear regression analysis with methylation as a continuous outcome (M-values) and age at menarche (>11 vs. ≤11 years) as a categorical exposure, adjusting for age, case-control status, and chip position. C. Q-Q plot on P-values from a linear regression analysis with methylation as a continuous outcome (M-values) and age at menarche (>11 vs. ≤11 years) as a categorical exposure, adjusting for age, case-control status, and chip position.</p

Logistic Regression for percent genome wide methylation (LUMA levels below vs. above median) by age at menarche as a categorical variable and other relevant confounders.

a<p>Each OR is adjusted for all other variables in the table.</p>*<p>Significant at the 0.05 level.</p

Subject demographic, anthropometric, lifestyle, and reproductive characteristics, by analysis stage.

*<p>Failure of category counts to add up to this value denotes missing values.</p>±<p>SD: Standard Deviation, BMI: Body Mass Index, FFTP: First Full Term Pregnancy, HRT: Hormone Replacement Therapy, OC: Oral Contraceptive.</p